Proteolytic inactivation of transforming growth factor β3 by elastase in venous leg ulcers: Implications for clinical trials using topically- applied peptide growth factors [2]

British Journal of Dermatology

Volumn 140, Issue 6, 1999, Pages 1170-1172

  Schmid, P ^a   Itin, P ^a   Cox, D ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1;

DOSE RESPONSE; DRUG EFFECT; HUMAN; IMMUNOTHERAPY; LEG ULCER; LETTER; PRIORITY JOURNAL; VEIN INSUFFICIENCY; WOUND HEALING;

GROWTH SUBSTANCES; HUMANS; LEG ULCER; LEUKOCYTE ELASTASE; TRANSFORMING GROWTH FACTOR BETA; WOUND HEALING;

EID: 0033022564     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)